Quick Links: Consensus Ratings,
Ratings History,
Earnings History,
Company Description
Consensus Ratings for Sanofi-Aventis (NYSE:SNY) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.| Ratings Breakdown: | 4 Hold Rating(s), 6 Buy Rating(s) |
| Consensus Rating: | Buy |
| Consensus Price Target: | $58.00 (5.36% upside) |
Analysts' Ratings History for Sanofi-Aventis (NYSE:SNY)| Date | Firm | Action | Company | Old Rating | New Rating | Old Price Target | New Price Target | Details |
|---|
| 5/13/2013 | TheStreet | Reiterated Rating | Sanofi-Aventis (SNY) | | Buy | | | View |
| 5/6/2013 | Zacks | Reiterated Rating | Sanofi-Aventis (SNY) | Neutral | Neutral | | $58.00 | View |
| 5/3/2013 | TheStreet | Reiterated Rating | Sanofi-Aventis (SNY) | | Buy | | | View |
| 4/22/2013 | TheStreet | Reiterated Rating | Sanofi-Aventis (SNY) | | Buy | | | View |
| 4/10/2013 | Sanford C. Bernstein | Set Price Target | Sanofi-Aventis (SNY) | | Outperform | $51.00 | $58.00 | View |
| 3/27/2013 | Deutsche Bank | Reiterated Rating | Sanofi-Aventis (SNY) | | Buy | | | View |
| 3/22/2013 | Zacks | Reiterated Rating | Sanofi-Aventis (SNY) | Neutral | Neutral | | $52.00 | View |
| 3/1/2013 | TheStreet | Reiterated Rating | Sanofi-Aventis (SNY) | | Buy | | | View |
| 2/19/2013 | TheStreet | Reiterated Rating | Sanofi-Aventis (SNY) | | Buy | | | View |
| 1/29/2013 | Barclays Capital | Downgrade | Sanofi-Aventis (SNY) | Overweight | Equal Weight | | | View |
| 1/28/2013 | Goldman Sachs | Upgrade | Sanofi-Aventis (SNY) | Conviction Sell | Neutral | | | View |
| 1/7/2013 | TheStreet | Reiterated Rating | Sanofi-Aventis (SNY) | | Buy | | | View |
| 12/28/2012 | Zacks | Reiterated Rating | Sanofi-Aventis (SNY) | Neutral | Neutral | | $50.00 | View |
| 12/14/2012 | Jefferies Group | Upgrade | Sanofi-Aventis (SNY) | Hold | Buy | | | View |
| 9/28/2012 | Zacks | Reiterated Rating | Sanofi-Aventis (SNY) | Neutral | Neutral | | $47.00 | View |
| 9/10/2012 | Bank of America | Upgrade | Sanofi-Aventis (SNY) | Neutral | Buy | | | View |
| 8/10/2012 | Cowen Securities | Upgrade | Sanofi-Aventis (SNY) | Neutral | Outperform | | | View |
| 8/3/2012 | Standpoint Research | Downgrade | Sanofi-Aventis (SNY) | Buy | Hold | | | View |
| 7/30/2012 | Zacks | Reiterated Rating | Sanofi-Aventis (SNY) | Neutral | Neutral | | $43.00 | View |
| 6/12/2012 | Zacks | Reiterated Rating | Sanofi-Aventis (SNY) | Neutral | Neutral | | $36.00 | View |
| 5/10/2012 | Societe Generale | Initiated Coverage | Sanofi-Aventis (SNY) | | Buy | | | View |
| 5/1/2012 | Zacks | Reiterated Rating | Sanofi-Aventis (SNY) | Neutral | Neutral | | $40.00 | View |
| 3/12/2012 | Zacks | Reiterated Rating | Sanofi-Aventis (SNY) | Neutral | Neutral | | $40.00 | View |
| 3/6/2012 | JPMorgan Chase | Upgrade | Sanofi-Aventis (SNY) | Neutral | Overweight | | | View |
| 2/1/2012 | Goldman Sachs | Downgrade | Sanofi-Aventis (SNY) | Neutral | Sell | | | View |
| 1/18/2012 | Bank of America | Downgrade | Sanofi-Aventis (SNY) | | Neutral | | | View |
| 1/5/2012 | JPMorgan Chase | Downgrade | Sanofi-Aventis (SNY) | Overweight | Neutral | | | View |
| 12/30/2011 | Zacks | Reiterated Rating | Sanofi-Aventis (SNY) | Neutral | Neutral | | $38.00 | View |
| 11/8/2011 | Zacks | Reiterated Rating | Sanofi-Aventis (SNY) | Neutral | Neutral | | $36.00 | View |
| 11/8/2011 | Collins Stewart | Downgrade | Sanofi-Aventis (SNY) | Hold | Sell | | | View |
| 9/9/2011 | Credit Suisse | Downgrade | Sanofi-Aventis (SNY) | Outperform | Neutral | | | View |
| 7/8/2011 | Sanford C. Bernstein | Upgrade | Sanofi-Aventis (SNY) | Market Perform | Outperform | | | View |
| 5/4/2011 | Bank of America | Upgrade | Sanofi-Aventis (SNY) | Neutral | Buy | | | View |
| 4/12/2011 | Zacks | Downgrade | Sanofi-Aventis (SNY) | Outperform | Neutral | | $39.00 | View |
| 1/11/2011 | Jefferies Group | Downgrade | Sanofi-Aventis (SNY) | Buy | Hold | | | View |
Click Here to view only the most recent ratings from each analyst for this stock.
Earnings History for Sanofi-Aventis (NYSE:SNY)No earnings history available
About Sanofi-Aventis
Sanofi-Aventis is a pharmaceutical group engaged in the research, development, manufacture and marketing of healthcare products. The Company's business includes two main activities: pharmaceuticals and human vaccines through sanofi pasteur. The Company is also present in animal health products through Merial Limited (Merial). In its pharmaceutical activity, the Company specializes in six therapeutic areas: diabetes, oncology, thrombosis and cardiovascular, central nervous system (CNS), and internal medicine. The global portfolio of sanofi-aventis also consists of a range of other pharmaceutical products in Consumer Health Care (CHC) and other prescription drugs, including generics. It offers vaccines in five areas: pediatric combination vaccines, influenza vaccines, adult and adolescent booster vaccines, meningitis vaccines and travel and endemic vaccines. In October 2010, Siegfried Holding AG sold its PulmoJet Inhalation Project to the Company.